These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27456338)

  • 41. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
    Männistö PT; Tuomainen P; Toivonen M; Törnwall M; Kaakkola S
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):31-43. PubMed ID: 2113389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
    Onzawa Y; Kimura Y; Uzuhashi K; Shirasuna M; Hirosawa T; Taogoshi T; Kihira K
    Biol Pharm Bull; 2012; 35(8):1244-8. PubMed ID: 22863920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.
    Pardo B; Mena MA; Casarejos MJ; Paíno CL; De Yébenes JG
    Brain Res; 1995 Jun; 682(1-2):133-43. PubMed ID: 7552304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
    Cedarbaum JM; Léger G; Reches A; Guttman M
    Clin Neuropharmacol; 1990 Dec; 13(6):544-52. PubMed ID: 2276119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen protects against dopamine neuron toxicity in primary mesencephalic cultures through an indirect P13K/Akt mediated astrocyte pathway.
    Bains M; Roberts JL
    Neurosci Lett; 2016 Jan; 610():79-85. PubMed ID: 26520464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium.
    Koutsilieri E; Chen TS; Rausch WD; Riederer P
    Eur J Pharmacol; 1996 Jun; 306(1-3):181-6. PubMed ID: 8813631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
    Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pergolide protects dopaminergic neurons in primary culture under stress conditions.
    Gille G; Rausch WD; Hung ST; Moldzio R; Janetzky B; Hundemer HP; Kolter T; Reichmann H
    J Neural Transm (Vienna); 2002 May; 109(5-6):633-43. PubMed ID: 12111455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M; Tuomainen P; Männistö PT
    Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
    Miyazaki I; Murakami S; Torigoe N; Kitamura Y; Asanuma M
    J Neurochem; 2016 Jan; 136(1):194-204. PubMed ID: 26485447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.